Lorena Martín-Zaragoza , Javier Sánchez-Rubio-Ferrández , Alberto Onteniente-González , Marcos Gómez-Bermejo , Sergio Julio Rodríguez-Álvarez , Alfonso Monereo-Alonso , Teresa Molina-García
{"title":"[译文]在艾滋病毒感染者中，多鲁特韦酯/拉米夫定与比特韦酯/恩曲他滨/替诺福韦-阿拉非那酰胺的实际持久性。","authors":"Lorena Martín-Zaragoza , Javier Sánchez-Rubio-Ferrández , Alberto Onteniente-González , Marcos Gómez-Bermejo , Sergio Julio Rodríguez-Álvarez , Alfonso Monereo-Alonso , Teresa Molina-García","doi":"10.1016/j.farma.2024.02.016","DOIUrl":null,"url":null,"abstract":"<div><h3>Objetives</h3><p>The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation.</p></div><div><h3>Methods</h3><p>We conducted a retrospective, non-interventional, descriptive, and longitudinal study. All human immunodeficiency virus <strong>(</strong>HIV) patients over 18 years treated with DTG/3TC or BIC/FTC/TAF in our center were included.</p><p>Persistence after first year was compared using the χ<sup>2</sup> test. Kaplan–Meier survival analysis was performed.</p></div><div><h3>Results</h3><p>Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (<em>p</em> <!-->=<!--> <!-->.001).</p><p>Persistence with DGT/3TC was 1237 days (IC95% 1216–1258) and persistence with BIC/FTC/TAF was 986 days [(IC95% 950–1021); <em>p</em> <!--><<!--> <!-->.001]. The difference was remained after adjusting for covariates with the cox regression model [HR<!--> <!-->=<!--> <!-->8.2 (IC95% 1.03–64.9), <em>p</em> <!-->=<!--> <!-->.047].</p><p>The main reasons for discontinuation for BIC/FTC/TAF were toxicity/tolerability.</p></div><div><h3>Conclusion</h3><p>In our study, patients have a high persistence. Patients on DTG/3TC treatment are more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF is tolerability/toxicity.</p></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1130634324000606/pdfft?md5=543fedfd0d261c18fbdf714cd6d15b97&pid=1-s2.0-S1130634324000606-main.pdf","citationCount":"0","resultStr":"{\"title\":\"[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV\",\"authors\":\"Lorena Martín-Zaragoza , Javier Sánchez-Rubio-Ferrández , Alberto Onteniente-González , Marcos Gómez-Bermejo , Sergio Julio Rodríguez-Álvarez , Alfonso Monereo-Alonso , Teresa Molina-García\",\"doi\":\"10.1016/j.farma.2024.02.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objetives</h3><p>The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation.</p></div><div><h3>Methods</h3><p>We conducted a retrospective, non-interventional, descriptive, and longitudinal study. All human immunodeficiency virus <strong>(</strong>HIV) patients over 18 years treated with DTG/3TC or BIC/FTC/TAF in our center were included.</p><p>Persistence after first year was compared using the χ<sup>2</sup> test. Kaplan–Meier survival analysis was performed.</p></div><div><h3>Results</h3><p>Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (<em>p</em> <!-->=<!--> <!-->.001).</p><p>Persistence with DGT/3TC was 1237 days (IC95% 1216–1258) and persistence with BIC/FTC/TAF was 986 days [(IC95% 950–1021); <em>p</em> <!--><<!--> <!-->.001]. The difference was remained after adjusting for covariates with the cox regression model [HR<!--> <!-->=<!--> <!-->8.2 (IC95% 1.03–64.9), <em>p</em> <!-->=<!--> <!-->.047].</p><p>The main reasons for discontinuation for BIC/FTC/TAF were toxicity/tolerability.</p></div><div><h3>Conclusion</h3><p>In our study, patients have a high persistence. Patients on DTG/3TC treatment are more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF is tolerability/toxicity.</p></div>\",\"PeriodicalId\":45860,\"journal\":{\"name\":\"FARMACIA HOSPITALARIA\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1130634324000606/pdfft?md5=543fedfd0d261c18fbdf714cd6d15b97&pid=1-s2.0-S1130634324000606-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"FARMACIA HOSPITALARIA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1130634324000606\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634324000606","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
[Translated article] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV
Objetives
The main objective was to compare the persistence between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir-alafenamide (BIC/FTC/TAF) and to analyze reasons for discontinuation.
Methods
We conducted a retrospective, non-interventional, descriptive, and longitudinal study. All human immunodeficiency virus (HIV) patients over 18 years treated with DTG/3TC or BIC/FTC/TAF in our center were included.
Persistence after first year was compared using the χ2 test. Kaplan–Meier survival analysis was performed.
Results
Three hundred fifty-eight patients were included. 99.5% versus 90.99% of patients were persistent after the first year for DTG/3TC and BIC/FTC/TAF respectively (p = .001).
Persistence with DGT/3TC was 1237 days (IC95% 1216–1258) and persistence with BIC/FTC/TAF was 986 days [(IC95% 950–1021); p < .001]. The difference was remained after adjusting for covariates with the cox regression model [HR = 8.2 (IC95% 1.03–64.9), p = .047].
The main reasons for discontinuation for BIC/FTC/TAF were toxicity/tolerability.
Conclusion
In our study, patients have a high persistence. Patients on DTG/3TC treatment are more persistent compared to BIC/FTC/TAF, although BIC/FTC/TAF have worse baseline characteristics. The main reason for discontinuation of BIC/FTC/TAF is tolerability/toxicity.
期刊介绍：
Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
